Novocure’s Optune receives positive coverage decision from Humana
Novocure, an oncology company based in Portsmouth, N.H., announced today that its portable, noninvasive brain tumor device Optune will now be covered by Humana, which becomes the ninth commercial payer in the U.S. to issue a positive coverage policy for the treatment.
That makes the device available to more than 107 million people across the United States, the company said in a press release.
Optune utilizes “tumor-treating fields”—alternating electric fields created within a tumor to prevent normal mitotic processes and cause cancer cell death—to deliver therapy to patients with newly diagnosed and recurrent glioblastoma.
Digital Editor
With nearly a decade of experience in print and digital publishing, John serves as Content Marketing Manager. His professional skill set includes feature writing, content marketing and social media strategy. A graduate of The Ohio State University, John enjoys spending time with his wife and daughter, along with a number of surprisingly mischievous indoor cacti.